1 – 8 of 8
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod
(
- Contribution to journal › Article
- 2018
-
Mark
Phase 3 assessment of the automated bone scan index as a prognostic imaging biomarker of overall survival in men with metastatic castration-resistant prostate cancer a secondary analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2016
-
Mark
Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis
(
- Contribution to journal › Article
-
Mark
Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer
(
- Contribution to journal › Article
- 2012
-
Mark
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus
(
- Contribution to journal › Article
- 2005
-
Mark
In vitro metabolism and in vivo pharmacokinetics of quinoline 3-carboxamide derivatives in various species
(
- Contribution to journal › Article
-
Mark
Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator
(
- Contribution to journal › Article
- 2004
-
Mark
Metabolism of quinoline 3-carboxamide compounds, a group of synthetic immunomodulators, in various species
2004)(
- Thesis › Doctoral thesis (compilation)